Natera

This video reflects on the progress we’ve made, with a gracious nod to what comes next at Natera. It brings together different perspectives, from how the outside world sees our work, to the voices of patients and families sharing what this experience looks like in their own words. It also reflects the work happening behind the scenes across teams and disciplines. Most of us know someone impacted by cancer, planning for a baby, or navigating life after a transplant. It’s something we think about every day, and we’re honored to support people through some of life’s most important moments. We’re proud of the progress. Grateful for the trust patients place in us. And clear on how much more there is to do. If you have a few minutes, it’s worth a watch.

The Thoracic Industry Showcase, sponsored by @NateraGenetics, is open now on Level 3. Learn about the latest innovations in #thoracic surgery now. #AATS2026

Identifying recurrence in early-stage melanoma requires high precision. As we observe Melanoma Awareness Month in May, we invite you to a clinical webinar focused on the multi-center, real-world data from, “Longitudinal ctDNA Monitoring for Post-Surgical Disease Surveillance in Patients with Stage I–IIIB Melanoma.” Register here: ow.ly/hcUB50YTArq Key topics include: • Tumor-informed ctDNA as a biomarker: Learn how ctDNA detection can provide early insight into melanoma recurrence and progression • Real-world evidence: Explore study findings on tumor-informed ctDNA-guided interventions and their potential to improve patient outcomes • Clinical applications: Understand how Signatera™ results may guide care decisions, including imaging escalation, therapy initiation, and management of molecular recurrence Featured speakers: George Ansstas, MD Michael Krainock, MD, PhD #MelanomaAwarenessMonth #Melanoma

Hello 👋 from booth #541 at #ACOG2026! Our team is here to share how Natera continues to advance prenatal genetic care. #Natera #ACOG @ACOG

See you at #ACOG2026! Stop by booth #541 to speak with our experts and explore how Natera continues to advance prenatal genetic care. There's still time to register for our dinner presentation, An Inside Look: Landmark EXPAND data supporting Fetal Focus™ and Natera’s future product roadmap, here: ow.ly/CQQc50YTcvk #Natera #ACOG @ACOG

Abhinand Peddada, MD, Pennington Cancer Institute, discusses using Signatera™ MRD testing to detect recurrence and guide treatment decisions for head and neck cancer patients. In this case, an asymptomatic rise in Signatera levels prompted a PET scan that identified subtle lung metastases, despite negative physical exams. This proactive approach allowed for early intervention with stereotactic ablation and immunotherapy. Watch the full presentation here: ow.ly/AFzy50YRQBj

Thank you for an incredible #ISHLT2026! With 17 abstracts, including six oral presentations, we showcased the clinical utility of Prospera™ in heart and lung transplantation. We also want to congratulate Michael Shullo, M.D., senior medical director, organ health at Natera, who was recognized in the inaugural class of @ISHLT fellows! ow.ly/LjXo50YRjSN

Join our upcoming webinar, Advancing testicular cancer management with ctDNA: Clinical utility of Signatera™ for MRD detection and surveillance with @DrJohnSfakianos, @nabiladra, and Ashley Wray, DMSc, MPH, PA-C. Register here: ow.ly/GH5n50YQLCt Learn more about: • Clinical performance of ctDNA vs conventional serum tumor markers (AFP, hCG) in germ cell tumors • Association of ctDNA positivity with recurrence risk in MRD and surveillance settings • Integration of ctDNA into post-orchiectomy and post-chemotherapy management decisions • Case-based discussion illustrating real-world clinical application

Join the upcoming webinar, From genotype to outcomes: Real-world evidence in glomerular diseases on April 29: ow.ly/ZkAA50YNCEV Hear from Ronen Schneider, Medical Director of Renal Genetics for Natera and moderator Dinah Clark, Director of Medical Education for Natera on the real-world evidence from RenasightIQ™ and how genetic drivers influence disease trajectory and therapeutic response.

Thank you everyone at #ISHLT2026 who attended our lung symposium, dd-cfDNA beyond rejection: Decoding molecular injury in lung transplantation. Our panel featured Jason Li, Transplant Fellow, Fatima Anjum, MD, MHA, Nirmal S. Sharma, MD, and Holly Keyt, MD. #Natera @ISHLT

TODAY: Don't miss our presentations at #ISHLT2026, including one featuring data from the TRIFECTA-Heart study and another highlighting the use of dd-cfDNA in lung transplantation. See the complete list of our presentations here: ow.ly/PqbP50YPate #transplantation #ISHLT @ISHLT

Brent Lampert, DO, presented the poster, dd-cfDNA Informs Clinical Decision-Making in Heart Transplantation: Insights from the ProTECT Study, at #ISHLT2026. Learn more: ow.ly/Q5Kv50YP3hc #Natera @ISHLT

Visit Natera at booth #205 to learn more about our Prospera™ test for heart and lung transplantation. See the full list of our abstracts here: ow.ly/9PEX50YOc71

A broad body of evidence supporting our Prospera™ test will be presented at the 2026 International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting this week. Prospera will be featured in 17 abstracts, including six oral presentations. Together with academic colleagues, our team will highlight Prospera’s expanding clinical utility in heart and lung transplantation, spanning rejection surveillance, imaging correlation, and real-world clinical decision-making. Read the full announcement and see the complete list of abstracts: ow.ly/b0Op50YO904 #ISHLT2026 #Natera @ISHLT

In support of National Infertility Awareness Week, we're proud to partner with organizations like @resolveorg, which provides resources and support for people on their family planning journey. #NIAW2026

🚀 This Lab Week, we are honored to celebrate our incredible laboratory teams who truly go "To Infinity and Beyond for Our Patients," @ASCP_Chicago’s theme for this year. Since our earliest days, our laboratory has served as the foundation for the insights on which individuals and families rely during their most pivotal moments. While our technology provides the platform, it is the care and expertise of our teams that transform every sample into a meaningful answer. Thank you, lab teams, for your continued contributions to our mission! #MedicalLaboratoryProfessionalsWeek #LabWeek #Natera

Members of our team attended the inaugural @BeckersHR Oncology Summit in Chicago this week. As a gold sponsor, Natera joined leading oncology executives and providers from across the country to discuss the latest trends shaping health system oncology service lines.

Congratulations to @AllogeneTx on the latest news regarding ALPHA3! Today, we issued a press release highlighting a positive interim futility analysis from the ALPHA3 trial, which is the first first MRD-guided randomized controlled trial in large b-cell lymphoma. The trial pairs Natera's phased variant MRD technology with cemacabtagene ansegedleucel (cema-cel), an investigational allogeneic anti-CD19 CAR T therapy developed by Allogene. Together with Allogene, we are committed to improving outcomes and transforming care for patients with lymphoma. Read more in our press release. ow.ly/Pf8C50YIuYk

Join us at Becker's Oncology Executive Summit and don't miss the Precision Oncology panel featuring Minetta Liu, Oncology and Early Cancer Detection, Natera. #MRD #ctDNA #Natera #BeckersAnnualMeeting @BeckersHR Learn more: ow.ly/SKKl50YIkNz

We're proud to support our partners at Head and Neck Cancer Alliance and learn more through their powerful features of survivors like Dr. Carla Burkley. Click below for resources and more information about ways to support events like the Move-A-Thon to participate in this hashtag#HeadAndNeckCancer Awareness Month! 💚💙